Hiroyuki Nakanoh

Dr. Hiroyuki Nakanoh


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Kenji TsujiKenji Tsuji
Kenji Tsuji
NUNaruhiko Uchida
Naruhiko Uchida
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SHSoichiro Haraguchi
Soichiro Haraguchi
JWJun Wada
Jun Wada
The gut–kidney axis represents the complex interactions between the gut microbiota and kidney, which significantly impact the progression of chronic kidney disease (CKD) and overall patient health. In CKD patients, imbalances in the gut microbiota promote the production of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, which impair renal function and contribute to systemic inflammation. Mechanisms like endotoxemia, immune activation and oxidative stress worsen renal damage by activating pro-inflammatory and oxidative pathways. Insights into these mechanisms highlight the impact of gut-derived metabolites, bacterial translocation, and immune response changes on kidney health, suggesting new potential approaches for CKD treatment. Clinical applications, such as dietary interventions, prebiotics, probiotics and fecal microbiota transplantation, are promising in adjusting the gut microbiota to alleviate CKD symptoms and slow disease progression. Current research highlights the clinical relevance of the gut–kidney axis, but further study is essential to clarify these mechanisms’ diagnostic biomarkers and optimize therapeutic interventions. This review emphasizes the importance of an integrated approach to CKD management, focusing on the gut microbiota as a therapeutic target to limit kidney injury.

18 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Kenji TsujiKenji Tsuji
Kenji Tsuji
NUNaruhiko Uchida
Naruhiko Uchida
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SHSoichiro Haraguchi
Soichiro Haraguchi
JWJun Wada
Jun Wada
The gut-kidney axis represents the complex interactions between the gut microbiota and renal function, which significantly impact the progression of chronic kidney disease (CKD) and overall patient health. On CKD patients, imbalances in the gut microbiota promote the production of uremic toxins like indoxyl sulfate and p-cresyl sulfate, which impair renal function and contribute to systemic inflammation. Mechanisms like endotoxemia, immune activation and oxidative stress worsen renal damage by activating pro-inflammatory and oxidative pathways. Insights into these mechanisms reveal the impact of gut-derived metabolites, bacterial translocation, and immune response changes on kidney health, suggesting new approaches for CKD treatment. Clinical applications like dietary interventions, prebiotics, probiotics and fecal microbiota transplantation show promise in adjusting the gut microbiota to alleviate CKD symptoms and slow disease progression. Current research highlights the clinical relevance of the gut-kidney axis, but further study is essential to clarify these mechanisms, diagnostic biomarkers, and optimize therapeutic interventions. This review emphasizes the importance of an integrated approach to CKD management, focusing on the gut microbiota as a therapeutic target to limit kidney injury.

9 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Kenji TsujiKenji Tsuji
Kenji Tsuji
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Acute kidney injury (AKI) is a clinical syndrome where a rapid decrease in kidney function and/or urine output is observed, which may result in the imbalance of water, electrolytes and acid base. It is associated with poor prognosis and prolonged hospitalization. Therefore, an early diagnosis and treatment to avoid the severe AKI stage are important. While several biomarkers, such as urinary L-FABP and NGAL, can be clinically useful, there is still no gold standard for the early detection of AKI and there are limited therapeutic options against AKI. miRNAs are non-coding and single-stranded RNAs that silence their target genes in the post-transcriptional process and are involved in a wide range of biological processes. Recent accumulated evidence has revealed that miRNAs may be potential biomarkers and therapeutic targets for AKI. In this review article, we summarize the current knowledge about miRNAs as promising biomarkers and potential therapeutic targets for AKI, as well as the challenges in their clinical use.

29 October 2025 in Life
Verified
Journal Article
Open access
PDF file
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
Kenji TsujiKenji Tsuji
Kenji Tsuji
KFKazuhiko Fukushima
Kazuhiko Fukushima
NUNaruhiko Uchida
Naruhiko Uchida
SHSoichiro Haraguchi
Soichiro Haraguchi
JWJun Wada
Jun Wada
Kidney organoids, derived from stem cells, including pluripotent stem cells and adult progenitor cells, have been reported as three-dimensional in vitro models that reflect key aspects of kidney development, structure, and function. Advances in differentiation protocols and tissue engineering have enabled the generation of organoids that exhibit nephron-like structures, including glomerular and tubular structures. Kidney organoids have been widely applied in several directions, including disease modeling and therapeutic screening, drug nephrotoxicity evaluation, and regenerative medicine. In particular, kidney organoids offer a promising platform for studying genetic kidney diseases, such as polycystic kidney disease and congenital anomalies of the kidney and urinary tract (CAKUT), by allowing patient-specific modeling for the analysis of pathophysiology and therapeutic screening. Despite several current limitations, such as incomplete maturation, lack of full nephron segmentation, and variability between protocols and cell conditions, further technological innovations such as microfluidics and bioengineering may refine kidney organoid systems. This review highlights recent advances in kidney organoid research, outlines major applications, and discusses future directions to enhance their physiological relevance, functional maturity, and translational integration into preclinical and clinical nephrology.

25 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
YSYizhen Sang
Yizhen Sang
Kenji TsujiKenji Tsuji
Kenji Tsuji
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence has revealed that excess SEMA3A expression and the subsequent signaling pathway aggravate kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports have demonstrated that the inhibition of SEMA3A ameliorated kidney injury via a reduction in cell apoptosis, fibrosis and inflammation; thus, SEMA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized the current knowledge regarding the role of SEMA3A in kidney pathophysiology and their potential use in kidney diseases.

31 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
YSYizhen Sang
Yizhen Sang
Kenji TsujiKenji Tsuji
Kenji Tsuji
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is the secreted and membrane-associated proteins, which regulate diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence revealed that excess SEMA3A expression and subsequent signaling pathway aggravates kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports demonstrated that inhibition of SEMA3A ameliorated kidney injury via reduction of cell apoptosis, fibrosis and inflammation, thus SE-MA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized current knowledges regarding the role of SEMA3A signaling in kidney pathophysiology and their potential use in kidney diseases.